Gain Early Access to the Neurotech Frontier
Kaleida Capital’s investment team is driven by neuroengineers with a proven ability to spot winners early— before they hit the mainstream radar.
Our Edge:
Deep scientific fluency— Neuroengineering PhD team with 10+ years in neural interfaces, diagnostics, and platform bioengineering
Proprietary sourcing—via academia, scientific networks, and targeted founder relationships
Investment rigor—valuation discipline, IP defensibility, and regulatory-aware screening
Early positioning in AI x neuroscience companies with asymmetric upside
How We Work with Investors:
Our model is designed for long-term partners who seek exposure to the neurotech frontier through both portfolio (Kaleida Capital Fund I, LP) and deal-by-deal (SPV) approaches.
We share deal flow selectively and only when conviction is high.